CAMCEVI

 

Category: Pharmaceutical

Exhibitor: FORESEE PHARMACEUTICALS CO., LTD.

Booth No: L122

 

Characteristic

 

CAMCEVI (leuprolide) is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer. Designed and developed through Foresee's pioneering Stabilized Injectable Formulation (SIF) technologies, CAMCEVI is the first successfully commercialized product, as well as the first leuprolide product that comes as a prefilled, ready-to-use long-acting depot injection requiring no mixing. CAMCEVI overcomes the requirement of manual reconstitution – an obstacle faced by the previous marketed leuprolide products, which can lead to handling inconvenience and potential risks of handing errors.
CAMCEVI 42 mg (6-month dosage), for the treatment of advanced prostate cancer, is approved in the U.S., Canada, EU, and Taiwan and launched in the U.S. in 2022.
CAMCEVI 21 mg (3-month dosage), for the treatment of advanced prostate cancer, is now approved in the U.S. in Aug. 2025; Canada and EU in 1H 2026.

 

 

 

Back